Of note, administration of the PGC-1α agonist bezafibrate has failed to improve mitochondrial biogenesis or muscle strength in Hq mice, with this treatment in fact inducing liver disease as a major adverse effect (41). The gene discussed is PPARGC1A; the disease is liver disorder.